Prostate cancer radiation in 2.5 Weeks: ‘Extreme’ but safe

Radiation oncologists in Scandinavia are experimenting with the boundaries of delivering radiation therapy for the treatment of intermediate-risk prostate cancer. In an ongoing open randomized phase 3 trial, they are comparing “extreme” hypofractionation, which was delivered in seven fractions across 2.5 weeks, with conventional treatment of 39 fractions across 8 weeks.